Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure.
about
Target organ cross talk in cardiorenal syndrome: animal models17ß-Estradiol regulates mTORC2 sensitivity to rapamycin in adaptive cardiac remodelingAngiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse modelRecurrent intradialytic paroxysmal atrial fibrillation: hypotheses on onset mechanisms based on clinical data and computational analysis.High-dose enalapril treatment reverses myocardial fibrosis in experimental uremic cardiomyopathyLeft ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease.Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycinRegression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: a controlled longitudinal studyPhosphate Metabolism in Cardiorenal Metabolic Disease.Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy.Myocardial dysfunction occurs prior to changes in ventricular geometry in mice with chronic kidney disease (CKD)Association of Left Ventricular Hypertrophy With a Faster Rate of Renal Function Decline in Elderly Patients With Non-End-Stage Renal Disease.Disentangling the ultrafiltration rate-mortality association: the respective roles of session length and weight gain.Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro-Fibrotic Signaling.Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats.Experimental models of renal disease and the cardiovascular system.Diastolic heart failure in dialysis patients: mechanisms, diagnostic approach, and treatment.Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.Aging and uremia: Is there cellular and molecular crossover?An Update on Intradialytic Cardiac Dysfunction.Cardiac actions of fibroblast growth factor 23.RGS4 controls renal blood flow and inhibits cyclosporine-mediated nephrotoxicity.Myocardial bioenergetic abnormalities in experimental uremiaPre-clinical model of severe glutathione peroxidase-3 deficiency and chronic kidney disease results in coronary artery thrombosis and depressed left ventricular function.Hypertrophied myocardium is vulnerable to ischemia/reperfusion injury and refractory to rapamycin-induced protection due to increased oxidative/nitrative stress.MiR-221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression.Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks.
P2860
Q26851343-EFDF53B4-BB5E-47CA-8366-0C37BB4486B0Q28546463-6F445F12-4CC1-465C-BFDE-25070AF57705Q30501039-072DF0CC-0967-40A1-A64E-BAE83D49B525Q30764530-FDC19526-0D65-4AC9-9062-5EF82F7F8C27Q33813308-C11B1392-0FB1-432A-BCD1-C02A66E49C0DQ33827358-2DF272B5-93DB-4BD8-8109-1EEA4A34DC31Q34627013-1E4A4436-C21F-4983-9A16-3C3A92CE63E5Q35154685-E9FC92D1-0071-49BC-A5C0-439F4C33B0FAQ35546322-C648D0DF-B064-476E-85F1-7C414925DCD1Q36104796-49D19F0D-A276-40DB-9977-FAF37BEA2366Q36773711-13739249-1F2D-45AC-8BD5-1D1CEDBD8156Q36836201-F2A4A595-43AE-41F1-AE7A-88CF67BC9E05Q36980336-529B15F8-940F-4AF3-BDB0-33E81123540DQ37434735-10B52420-7F03-4E9F-AE54-698CB51F9CD1Q37690771-53C954F4-7A03-4F23-A83E-6DBBD54641A8Q37831804-BEA330BC-665B-4EF3-8CA4-2826CE58B368Q37978426-A1488580-900E-4ACE-9102-E995FECB2C3DQ38258133-16F633C5-F2BF-4994-93B1-988241DDE91FQ38348935-D3DA27E4-2C64-4B93-951C-47C09052792BQ38807482-89E890EA-F0CE-4A7A-B7FD-8F4E64391394Q38977291-480FA2EC-85C2-4261-86C5-60AEEE5DC095Q39270508-B20327C9-F241-462E-A3CE-F230D347867EQ39679729-5D23D633-26C7-487B-B866-7A68443B07F2Q46240455-44AD9D95-E941-4A16-BA01-D540F2848158Q49629102-6621651C-E533-4502-A048-7F29569A59EEQ51438277-4CBC70CF-F37D-4E35-9894-4D4CE0835EFFQ51443453-1F324389-53A6-4A64-8217-AE1C370D0F57
P2860
Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Uremic cardiac hypertrophy is ...... by lowering of blood pressure.
@en
type
label
Uremic cardiac hypertrophy is ...... by lowering of blood pressure.
@en
prefLabel
Uremic cardiac hypertrophy is ...... by lowering of blood pressure.
@en
P2093
P2860
P356
P1433
P1476
Uremic cardiac hypertrophy is ...... by lowering of blood pressure.
@en
P2093
Andrew M Siedlecki
Anthony J Muslin
Xiaohua Jin
P2860
P2888
P304
P356
10.1038/KI.2008.690
P407
P577
2009-01-21T00:00:00Z